1. DaVita ( DVA) provides dialysis services in the U.S. for patients suffering from chronic kidney failure. The company provides in-patient hemodialysis services in approximately 750 hospitals, excluding physician services. DaVita will announce third-quarter results on Nov. 3. For the third quarter of 2011, net income is seen at $137.75 million, vs. $119.39 million recorded in the year-ago quarter. Also, for the same period, net sales are seen growing to $1.79 billion from $1.65 billion. Earnings per share for the quarter are expected to increase to $1.44 from $1.15 per share in the year-ago period. Gross margin is seen expanding to 33.03% from 30.59% earlier. Operating profit is at $2.34 billion, up 12%. Cash flow per share is pegged at $2.05 for the quarter, up 30%. Of the 17 analysts covering the stock, 76% recommend a buy and the rest suggest a hold. There are no sell ratings on the stock. On an average, analysts polled by Bloomberg expect the stock to gain almost 19.5% to $86.08 from current levels over the next 12 months. >>To see these stocks in action, visit the 8 Health Care Buys Ahead of Earnings portfolio on Stockpickr.